*Baylor College of Medicine, Houston, TX
†Shire Pharmaceuticals, Wayne, PA
Funding/Support: Shire Development Inc., Wayne, PA.
Acknowledgment: The authors take full responsibility for the data and editorial content of this manuscript and provided significant input to the content and revisions to the manuscript. The authors would like to express appreciation for editorial assistance, copyediting, and evidence verification, from Robert Gregory and William Perlman of Excerpta Medica, Bridgewater, NJ. Their services were funded by Shire Develop ment, Inc., Wayne, PA.
Disclosures: Dr Mao has served as a consultant for Lilly, Novartis, and Shire Pharmaceuticals. She has been on the lecture bureau for Lilly, McNeil, Shire, Bristol-Myers Squibb, Novartis, and Pfizer. Dr Babcock is a full-time employee of Shire Development, Inc. Dr Brams has received research support from Novartis, Shire, Lilly, and Otsuka. He has served as a consultant for Lilly, Novartis, and Shire, and has been on the lecture bureau for AstraZeneca, GlaxoSmithKline, McNeil, Novartis, Pfizer, and Shire.
Please send correspondence to: Alice R. Mao, MD, Associate Professor of Psychiatry, Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, 500 Westcott Drive, Suite 520, Houston, TX 77007. [email protected]
